[go: up one dir, main page]

WO2008120711A1 - タミバロテンカプセル剤 - Google Patents

タミバロテンカプセル剤 Download PDF

Info

Publication number
WO2008120711A1
WO2008120711A1 PCT/JP2008/056073 JP2008056073W WO2008120711A1 WO 2008120711 A1 WO2008120711 A1 WO 2008120711A1 JP 2008056073 W JP2008056073 W JP 2008056073W WO 2008120711 A1 WO2008120711 A1 WO 2008120711A1
Authority
WO
WIPO (PCT)
Prior art keywords
tamibarotene
oily component
capsule preparation
preferable
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/056073
Other languages
English (en)
French (fr)
Inventor
Hisao Ekimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TMRC Co Ltd
Original Assignee
TMRC Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TMRC Co Ltd filed Critical TMRC Co Ltd
Priority to EP08739191.8A priority Critical patent/EP2143428B1/en
Priority to HK10105224.5A priority patent/HK1137367B/xx
Priority to CN2008800098642A priority patent/CN101641091B/zh
Priority to US12/593,866 priority patent/US8252837B2/en
Priority to NZ580209A priority patent/NZ580209A/en
Priority to AU2008233631A priority patent/AU2008233631B2/en
Priority to MX2009009997A priority patent/MX2009009997A/es
Priority to JP2009507513A priority patent/JP5539713B2/ja
Priority to CA2681712A priority patent/CA2681712C/en
Priority to ES08739191.8T priority patent/ES2559420T3/es
Publication of WO2008120711A1 publication Critical patent/WO2008120711A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

　生体内への吸収性が高く、上述の毒性を最小限に抑え、汚染の心配のない安全で安定性のある、実用的なタミバロテンの製剤形態および投与形態を提供する。 　油性成分を基剤とし、該基剤にタミバロテンが有効成分として溶解する組成物が封入されてなるタミバロテンカプセル剤である。好ましくは、前記油性成分がプロピレングリコール脂肪酸エステル類またはポリエチレングリコール類である。また、前記油性成分に対し、前記タミバロテンを０．１～５０ｍｇ／ｍＬ含むことが好ましい。
PCT/JP2008/056073 2007-03-30 2008-03-28 タミバロテンカプセル剤 Ceased WO2008120711A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP08739191.8A EP2143428B1 (en) 2007-03-30 2008-03-28 Tamibarotene capsule preparation
HK10105224.5A HK1137367B (en) 2007-03-30 2008-03-28 Tamibarotene capsule preparation
CN2008800098642A CN101641091B (zh) 2007-03-30 2008-03-28 他米巴罗汀胶囊剂
US12/593,866 US8252837B2 (en) 2007-03-30 2008-03-28 Tamibarotene capsule preparation
NZ580209A NZ580209A (en) 2007-03-30 2008-03-28 Tamibarotene capsule preparation
AU2008233631A AU2008233631B2 (en) 2007-03-30 2008-03-28 Tamibarotene capsule preparation
MX2009009997A MX2009009997A (es) 2007-03-30 2008-03-28 Preparacion de la capsula de tamibarotene.
JP2009507513A JP5539713B2 (ja) 2007-03-30 2008-03-28 タミバロテンカプセル剤
CA2681712A CA2681712C (en) 2007-03-30 2008-03-28 Tamibarotene capsule preparation
ES08739191.8T ES2559420T3 (es) 2007-03-30 2008-03-28 Preparado de cápsulas de Tamibaroteno

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007092604 2007-03-30
JP2007-092604 2007-03-30

Publications (1)

Publication Number Publication Date
WO2008120711A1 true WO2008120711A1 (ja) 2008-10-09

Family

ID=39808291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056073 Ceased WO2008120711A1 (ja) 2007-03-30 2008-03-28 タミバロテンカプセル剤

Country Status (10)

Country Link
US (1) US8252837B2 (ja)
EP (1) EP2143428B1 (ja)
JP (1) JP5539713B2 (ja)
KR (1) KR20100016048A (ja)
CN (1) CN101641091B (ja)
CA (1) CA2681712C (ja)
ES (1) ES2559420T3 (ja)
MX (1) MX2009009997A (ja)
NZ (1) NZ580209A (ja)
WO (1) WO2008120711A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101708168B (zh) * 2009-12-02 2011-07-20 深圳万乐药业有限公司 一种他米巴罗汀分散片的制备方法
CN101829044B (zh) * 2009-03-13 2013-02-20 北京本草天源药物研究院 一种他米巴罗汀固体制剂及其制备方法
JP2013199458A (ja) * 2012-03-26 2013-10-03 Tmrc Co Ltd カプセル製剤
JP2016518342A (ja) * 2013-03-15 2016-06-23 アヴィセンナ・コスメティクス・エルエルシーAvisenna Cosmetics, Llc 加齢の影響を軽減するための局所組成物
JP2024081713A (ja) * 2015-03-31 2024-06-18 サイロス ファーマシューティカルズ， インコーポレイテッド レチノイン酸受容体－αアゴニストによる処置のための患者を層別化する方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6295249B2 (ja) * 2012-06-07 2018-03-14 チルドレンズ ホスピタル ロサンゼルス レチノイドアゴニストを用いた好中球減少症の治療方法
WO2015045037A1 (ja) * 2013-09-25 2015-04-02 テムリック株式会社 カプセル製剤
MX2016010699A (es) 2014-02-18 2017-10-11 Children's Hospital Los Angeles Composiciones y metodos para tratar neutropenia.
CN104162167A (zh) * 2014-07-18 2014-11-26 山东大学 他米巴罗汀环糊精或环糊精衍生物包合物及其制备方法
DK3380086T3 (da) 2015-11-25 2021-11-22 Io Therapeutics Inc Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
CN115737821B (zh) 2016-04-08 2024-04-12 赛罗斯制药有限公司 用于治疗aml和mds的rara激动剂
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2020205957A1 (en) * 2019-04-02 2020-10-08 Transgenex Nanobiotech, Inc. Novel ternary molecular complex of tamibarotene for cancer stem cells treatment

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6176440A (ja) 1984-09-19 1986-04-18 Koichi Shiyudo 安息香酸誘導体
JPH0525037A (ja) * 1991-07-01 1993-02-02 Upjohn Co:The 経口投与酵素感受性腸溶製剤
JPH0717854A (ja) * 1993-04-05 1995-01-20 Koichi Shudo 抗骨疾患剤
JPH07196478A (ja) 1993-12-30 1995-08-01 Hajime Sugii 安全性の高い食品及び医薬品用ソフトカプセル
JPH10251144A (ja) * 1997-03-11 1998-09-22 Iyaku Bunshi Sekkei Kenkyusho:Kk インターロイキン−６産生阻害剤
JP3001632B2 (ja) 1990-03-20 2000-01-24 首藤 紘一 安息香酸誘導体の新規製造法
WO2002018322A1 (en) 2000-09-01 2002-03-07 Toko Pharmaceutical Ind. Co., Ltd. Process for the production of crystals of a benzoic acid derivative
WO2003094897A1 (en) * 2002-05-09 2003-11-20 Chugai Seiyaku Kabushiki Kaisha Photostabilized soft capsule

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316917A (en) * 1980-04-21 1982-02-23 Hoffman-La Roche Inc. Stable carotenoid solutions
US4808631A (en) * 1986-11-07 1989-02-28 Hoffmann-La Roche Inc. Aromatic acid derivatives
EP0619116A3 (en) * 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
CN1660064B (zh) * 2004-12-28 2010-09-29 中山大学 那格列奈自乳化释药系统

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6176440A (ja) 1984-09-19 1986-04-18 Koichi Shiyudo 安息香酸誘導体
JP3001632B2 (ja) 1990-03-20 2000-01-24 首藤 紘一 安息香酸誘導体の新規製造法
JPH0525037A (ja) * 1991-07-01 1993-02-02 Upjohn Co:The 経口投与酵素感受性腸溶製剤
JPH0717854A (ja) * 1993-04-05 1995-01-20 Koichi Shudo 抗骨疾患剤
JPH07196478A (ja) 1993-12-30 1995-08-01 Hajime Sugii 安全性の高い食品及び医薬品用ソフトカプセル
JPH10251144A (ja) * 1997-03-11 1998-09-22 Iyaku Bunshi Sekkei Kenkyusho:Kk インターロイキン−６産生阻害剤
WO2002018322A1 (en) 2000-09-01 2002-03-07 Toko Pharmaceutical Ind. Co., Ltd. Process for the production of crystals of a benzoic acid derivative
WO2003094897A1 (en) * 2002-05-09 2003-11-20 Chugai Seiyaku Kabushiki Kaisha Photostabilized soft capsule

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FANJUL A.N. ET AL.: "Potential Role for Retinoic Acid Receptorin the Inhibition of Breast Cancer Cells by Selective Retinoids and Interferons", CANCER RESEARCH, vol. 56, 1996, pages 1571 - 1577, XP001009864 *
See also references of EP2143428A4

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101829044B (zh) * 2009-03-13 2013-02-20 北京本草天源药物研究院 一种他米巴罗汀固体制剂及其制备方法
CN101708168B (zh) * 2009-12-02 2011-07-20 深圳万乐药业有限公司 一种他米巴罗汀分散片的制备方法
JP2013199458A (ja) * 2012-03-26 2013-10-03 Tmrc Co Ltd カプセル製剤
JP2016518342A (ja) * 2013-03-15 2016-06-23 アヴィセンナ・コスメティクス・エルエルシーAvisenna Cosmetics, Llc 加齢の影響を軽減するための局所組成物
US11039995B2 (en) 2013-03-15 2021-06-22 Samson Pharma, Llc Topical compositions for reducing the effects of aging
JP2024081713A (ja) * 2015-03-31 2024-06-18 サイロス ファーマシューティカルズ， インコーポレイテッド レチノイン酸受容体－αアゴニストによる処置のための患者を層別化する方法

Also Published As

Publication number Publication date
EP2143428A1 (en) 2010-01-13
CN101641091B (zh) 2012-09-19
JPWO2008120711A1 (ja) 2010-07-15
MX2009009997A (es) 2009-12-08
CN101641091A (zh) 2010-02-03
EP2143428B1 (en) 2015-11-04
ES2559420T3 (es) 2016-02-12
JP5539713B2 (ja) 2014-07-02
US8252837B2 (en) 2012-08-28
KR20100016048A (ko) 2010-02-12
HK1137367A1 (en) 2010-07-30
CA2681712C (en) 2013-05-07
US20100048708A1 (en) 2010-02-25
NZ580209A (en) 2011-11-25
AU2008233631A1 (en) 2008-10-09
CA2681712A1 (en) 2008-10-09
EP2143428A4 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
WO2008120711A1 (ja) タミバロテンカプセル剤
UA102477C2 (en) Capsule composition
WO2005063218A3 (en) Pharmaceutical formulations of bisphosphonates
WO2006014673A3 (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2002067864A3 (en) Coenzyme q products exhibiting high dissolution qualities
WO2010117873A3 (en) Progesterone solutions for increased bioavailability
WO2003013497A1 (en) Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
WO2007117706A3 (en) Solid oral dosage form containing an enhancer
WO2010032140A3 (en) Pharmaceutical compositions and related methods of delivery
WO2011038278A3 (en) Micelle encapsulation of therapeutic agents
UA100234C2 (uk) Рідкі препарати гербіцидів - похідних сульфонілсечовини
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
EP1750862A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
WO2005110398A3 (en) Pharmaceutical solution formulations containing 17-aag
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
RU2010120706A (ru) Композиция липоевой кислоты в виде шариков
WO2007014124A3 (en) High drug load formulations and dosage forms
WO2005065639A3 (en) Novel pharmaceutical compositions
EP1679063A4 (en) NEW LIQUID PREPARATE COMPOSITION
DE502004008949D1 (de) Physiologisch aktive zusammensetzung auf phosphatidylserin-basis
WO2003045305A3 (en) Acetaminophen compositions
IL174336A0 (en) Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
CA2556520A1 (en) Chromium-fatty acid compounds and methods of making and using thereof
EA200700735A1 (ru) Капсулы лерканидипина
WO2005115346A3 (en) Pharmaceutical composition containing risperidone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880009864.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739191

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009507513

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/009997

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2681712

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12593866

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 580209

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008233631

Country of ref document: AU

Ref document number: 1909/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008739191

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097022673

Country of ref document: KR

Kind code of ref document: A